Affinia Therapeutics
PrivateLast Round
Series C
Oct 7, 2025
Est. Valuation
$145M
Total Funding Raised
$210M
Momentum Score
25 /100
Company Overview
Affinia Therapeutics is a biotechnology company specializing in the development of AAV vectors and gene therapies aimed at treating severe diseases impacting the central nervous system and muscles.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Affinia Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Affinia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 7, 2025 | ||||
| Series B | May 3, 2021 | ||||
| Series A | Mar 31, 2020 |
Key People
Founding team and executive leadership
Affinia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| RA Capital Management | Series B |
| Farallon Capital Management | Series B |
| TCG Crossover | Series B |
| GV | Series C, Series B |
| Perceptive Advisors | Series C, Series B |
| New Enterprise Associates (NEA) | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
Presenting data on AFTX-201 program for bag3-associated DCM at upcoming conference.
- Apr 28, 2026
Presenting data at the American Society of Gene & Cell Therapy 2026 Annual Meeting.
Affinia Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Affinia Therapeutics's valuation, stock price, and market status.
